Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer

Journal of Immunotherapy

Volumn 23, Issue 5, 2000, Pages 570-580

  Scholl, Susy M ^a   Balloul, Jean Marc ^b   Le Goc, Gwenaelle ^b   Bizouarne, Nadine ^b   Schatz, Christian ^b   Kieny, Marie Paule ^b   von Mensdorff Pouilly, Sylvia ^b   Vincent Salomon, Anne ^a   Deneux, Laurent ^a   Tartour, Eric ^a   Fridman, Wolf ^a   Pouillart, Pierre ^b   Acres, Bruce ^b  

^a TRANSGENE S A   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Immunotherapy; MUC; Recombinant vaccinia virus

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 2; MEMBRANE PROTEIN; RECOMBINANT VACCINE; TG 1031; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MEMORY CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR BIOPSY; VACCINIA VIRUS;

ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CANCER VACCINES; CYTOKINES; DNA, COMPLEMENTARY; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHATIC METASTASIS; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

EID: 0033852076     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200009000-00007     Document Type: Article

References (19)

1. Scholl S, Pouillart P. Vaccination against the polymorphic epithelial mucine MUC1 commonly overexpressed in breast cancer. Bull Cancer 1997; 84:61-4.
2. Graham RA, Burchell JM, Taylor-Papadimitriou. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42:71-81.
3. Agrawal B, Reddish MA, Krantz MJ, Longenecker M. Does pregnacy immunize against breast cancer? Cancer Res 1995; 55:2257-61.
4. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumors. Eur J Cancer 1996; 32A:1325-31.
5. Kotera Y, Fontenot JD, Pecher G, Metzgard RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54:2856-60.
6. Acres RB, Hareuveni M, Balloul JM, Kieny MP. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunol 1993; 14:136-43.
7. Keydar I, Chou CS, Hareuveni M, et al. Production and characterization of monoclonal antibodies identifying breast tumour-associated antigens. Proc Natl Acad Sci USA 1989; 86:1362-6.
8. Buller R, Smith G, Cremer K, Notkins A, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase negative phenotype. Nature 1985; 317:813-15.
9. Bizouarne N, Balloul JM, Schatz C, Acres B, Kieny MP. Immunotherapy of breast cancer using a recombinant vaccinia virus expressing the human MUC1 and IL2 genes. In: Calvo F, Crépin M, Magdalenat H, eds. Breast cancer, advances in biology and therapeutic. Montrouge: John Libby Eurotext; 1996:303.
10. Acres B, Apostolopoulos V, Balloul JM, et al. MUC1-specific cytotoxic T cell precursor analysis in human MUC1 transgenic mice immunized with human MUC1 vaccines. Cancer Immunol Immunother 2000; 48:588-94.
11. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol 1998; 19:186-95.
12. Tartour E, Gey A, Sastre-Garau X, et al. Intratumoral IFN Gamma mRNA expression in invasive cervical carcinomas: relationship with clinical outcome and HLA class II expression by tumor cells. J Natl Cancer Instit 1998; 4:287-94.
13. Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 1987; 330:259-62.
14. Baron C, Scholl S, Bausinger H, et al. Two distinct cell populations are obtained from human blood monocytes cultured with M-CSF, GR-CSF and IL4. Eur J Cancer 1999; 35(Suppl. 3):539-40.
15. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7.
16. Brochier B, Kieny MP, Costy F, et al. Large scale eradication of rabies using recombinant mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition. J Immunother 1993; 14:127-35.
17. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T cell proliferation, which is reversible by IL2. Nat Med 1998; 4:43-9.
18. Gimmi C, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996; 2:1367-70.
19. Apostolopoulos V, Osinski C, McKenzie I. Muc1 cross reactive Gala(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 1998; 4:315-20.